Boston Scientific has initiated multiple worldwide product recalls, including a Class I recall of its ENROUTE Transcarotid Neuroprotection System due to risks of arterial sheath tip separation, and Class II recalls of certain OverStitch Suture Cinch endoscopic devices citing deployment and suture cutting failures. The Class I recall affects 164,687 neuroprotection units across two product versions, while the Class II recalls cover 60,654 standard units plus additional long versions. These products are distributed worldwide and are used in high-acuity procedures, so the field actions could disrupt physician workflows and reorder patterns. The recalls add operational, regulatory, and reputational pressures for Boston Scientific in 2026, and investors will watch for the company's formal update on recall-related costs, remediation timing, and any sales or margin impact in its next earnings report.
Boston Scientific CorpMultiple worldwide recalls, including a Class I recall, create regulatory and reputational pressures.
